Showing 4951-4960 of 8785 results for "".
- Soliton Names New President and CEOhttps://practicaldermatology.com/news/soliton-names-new-president-and-ceo/2460593/Brad A. Hauser is the new President and Chief Executive Officer of Soliton. He most recently served as Vice President, R&D and General Manager for CoolSculpting at Allergan Aesthetics, an AbbVie Company, since Allergan's April 2017
- AbbVie Presents Additional Phase 3 Data for Upadacitinibhttps://practicaldermatology.com/news/abbvie-presents-additional-phase-3-data-on-upadacitinib/2460591/Significantly more patients treated with AbbVie’s upadacitinib in both of the Measure Up 1 and 2 studies
- EADV Congress Update: Insights on Psoriasis, AD, UV Protection, COVID-19, and Morehttps://practicaldermatology.com/news/eadv-congress-update-insights-on-psoriasis-ad-uv-protection-covid-19-and-more/2460588/From updates on investigational treatments for dermatologic diseases to emerging healthcare trends, data from the 29th EADV Congress, EADV Virtual suggest new directions in patient care. Psoriasis: Results from the phas
- Coping with COVID-19: ‘Long-hauler’ COVID-19 Patients Experience Prolonged Skin Symptomshttps://practicaldermatology.com/news/coping-with-covid-19-long-hauler-covid-19-patients-experience-prolonged-skin-symptoms/2460584/Some COVID-19 patients experience long-lasting skin symptoms that vary according to type of COVID-19 skin rash, according to a late-breaking abstract presented at the 29th EADV Congress, EADV Virtual. The analysis of the largest registry of COVID-19 patients with dermatological sym
- Dermatologist Named AAD Patient Hero for Saving South Florida Man’s Life with Early Diagnosis of Lung Cancerhttps://practicaldermatology.com/news/dermatologist-named-aad-patient-hero-for-saving-south-florida-mans-life-with-early-diagnosis-of-lung-cancer/2460583/Brittany Smirnov, DO is an American Academy of Dermatology Patient Care Hero for her role in diagnosing and treating a patient with stage IV metastatic lung cancer. When South Florida resident Richard Danzer developed a cyst on his back that grew larger and more painful over t
- Dermatologist Named AAD Patient Hero for Providing Skin Care to People Experiencing Homelessness Amid COVID-19https://practicaldermatology.com/news/dermatologist-names-aad-patient-hero-for-providing-skin-care-to-people-experiencing-homelessness-amid-covid-19/2460582/Jennifer Tan, MD, FAAD is an American Academy of Dermatology (AAD) Patient Care Hero for making critical skin care and hygiene items easily accessible to individuals experiencing homelessness during the COVID-19 pandemic. As the state government issued COVID-19 stay-at-home guidanc
- FDA Grants Priority Review for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe ADhttps://practicaldermatology.com/news/fda-grants-priority-review-for-pfizers-abrocitinib-an-oral-once-daily-jak1-inhibitor-for-patients-12-and-up-with-moderate-to-severe-ad/2460580/The U.S. Food and Drug Administration (FDA) has granted Priority Review designation to Pfizer’s New Drug Application (NDA) for abrocitinib (100mg and 200mg), an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate to severe atopic dermatitis (AD) in
- The HydraFacial Company And Circadia Expand Partner Boosters Globallyhttps://practicaldermatology.com/news/the-hydrafacial-company-and-circadia-expand-partner-boosters-globally/2460579/The HydraFacial Company is extending their partnership with Circadia to offer the Chrono-Peptide Booster and ProTec Plus Booster to HydraFacial providers in more than 40 countries. "The Circadia boosters for HydraFacial are already loved by providers and consume
- Arcutis: Phase 1/2b Enrollment Complete for ARQ-252 in Chronic Hand Eczemahttps://practicaldermatology.com/news/arcutis-phase-12b-enrollment-complete-for-arq-252-in-chronic-hand-eczema/2460578/Arcutis Biotherapeutics, Inc. has completed enrollment in the Phase 1/2b studyof its Janus kinase type 1(JAK1) ARQ-252 in adult patients with chronic hand eczema. Arcutis has updated its projected topline data from this trial to mid-2021.
- Soligenix's Phase 3 FLASH Study Continues to Demonstrate Positive Benefits of SGX301 in Cutaneous T-Cell Lymphoma Patientshttps://practicaldermatology.com/news/soligenixs-phase-3-flash-study-continues-to-demonstrate-positive-benefits-of-sgx301-in-cutaneous-t-cell-lymphoma-patients/2460576/Continued optional treatment with Soligenix, Inc.’s SGX301 (synthetic hypericin) demonstrates positive benefits in patients with cutaneous T-Cell lymphoma Nearly half of all patients in Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) trial conti